Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biosimilar User Fee Revenue Missed Estimates Again In FY 2019, Spending Reduced

Jun 23 2020

• By Derrick Gingery

Money Wave — Estimates of future BsUFA revenue indicate substantial increases compared to FY 2019 collections. • Source: Shutterstock

Related Content

PDUFA VII: Will Gene Therapy's Rise Influence Talks?

Feb 04 2020

FDA May Not Implement User Fee Workload Adjuster In PDUFA VI

Apr 02 2018

Biosimilar User Fee Collections Drop Well Below Estimates, But US FDA Not Worried

Jun 10 2019

After Biosimilar Fee Collections Fall Short, US FDA Modifies Carryover Spend-Down Plan

Oct 09 2019

Biosimilars Program Will Be “Under-Resourced” In Early Years As Industry Grows

Sep 13 2012

Additional Topics

United States Biosimilars User Fees FDA Regulation Review Pathway BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window